The Challenges of Pertussis Outbreaks in Healthcare Facilities: Is There A Light at the End of the Tunnel?

Kathryn M. Edwards, MD; Thomas R. Talbot, MD, MPH

Although classically recognized as a disease of infants and children, the reported incidence of Bordetella pertussis infection in adolescents and adults has increased at a remarkable rate over the past decade. During 2004, more than 25,000 cases of pertussis were reported to the Centers for Disease Control and Prevention (CDC), the highest total since 1959; of these, 34% were in individuals aged 11-18 years and 29% were in adults aged 19 years and older. This increase in pertussis in adolescents and adults is likely due to several factors, including waning protection from childhood vaccination and natural infection, an increased appreciation of disease in this age group, and the improved ability of clinicians to diagnose pertussis through the use of serologic methods. Whether this increase in pertussis incidence represents a true increase in disease or just reflects an improved recognition of disease remains unclear. However, what is clear is, first, that rates of pertussis are also increasing in infants, and second, that adolescents and adults serve as a source of contagion for infants and young children, who suffer the greatest morbidity, and even mortality, from pertussis. Despite high rates of routine pertussis vaccination among children, rates of pertussis disease continue to climb, and it is becoming a major public health problem.

Healthcare-associated outbreaks of pertussis also have been increasingly recognized and reported from a diverse range of healthcare facilities, such as residential homes for mentally or physically impaired persons, pediatric wards and nurseries, emergency departments, and hematology-oncology care units. Such outbreaks are often the result of under-recognition of pertussis and subsequent failure to isolate patients with suspected infection, as well as the increasing incidence of pertussis among adults and adolescents. Healthcare workers (HCWs) are at increased risk for acquiring B. pertussis infection; one study estimates that there is a 1.7-fold increased risk for HCWs, compared with the general population. A serologic analysis of samples from emergency department HCWs at Vanderbilt University Medical Center revealed annual incidence rates of 1.3 infections per 100 persons among emergency department resident physicians and 3.6 infections per 100 persons among patient care staff. This increased risk is likely the result of regular contact with infected patients and waning protection from childhood vaccination or natural B. pertussis infection. Infected HCWs can then serve as vectors of infection to other susceptible contacts, including patients, other employees, and even their own children.

Nosocomial exposure to B. pertussis results in substantial disruptions and costs to the healthcare system, to HCWs, and to individual contacts. Costs include, but are not limited to, person-hours spent by infection control and occupational health staff investigating the contacts of an index patient and of exposed persons, laboratory evaluation of symptomatic contacts, antimicrobial prophylaxis for exposed individuals, efforts to alert communities of pertussis outbreaks, uncompensated medical costs borne by contacts, and loss of productivity and wages from HCWs who are ill and/or furloughed. As would be expected, such costs are not trivial. For example, an evaluation of employees and patients exposed to 3 HCWs with documented pertussis in a French hospital cost more than €46,000, with 42% of that figure the result of productivity losses. In another healthcare-associated outbreak of pertussis in 17 HCWs exposed to an infected infant, the evaluation of 307 HCW contacts resulted in more than $81,000 in total measured costs.

In this issue of the journal, several articles complement our growing knowledge about nosocomial pertussis outbreaks. Three of them highlight the role of adults in transmission of pertussis to infants, the deficiencies in the healthcare setting that allow B. pertussis transmission to occur readily, and the challenges in managing nosocomial exposures to pertussis. Perhaps the most distressing account is the article by Bryant et al., which describes a severe B. pertussis infection in a premature infant that was traced back to an ill HCW. As noted by the authors, “despite paroxysms, whoop, post-tussive emesis, a spontaneous pneumothorax, and multiple visits for medical care, pertussis was not suspected [in the...
HCW] until diagnosis of the infant case” (p. 543). In total, 79 patients and 72 HCWs received postexposure treatment. Although recent publications have highlighted that pertussis is responsible for 7%-32% of cough illnesses that last 1 week or longer in adolescents and adults,17-19 many clinicians fail to recognize the disease, and most have great difficulty with laboratory confirmation of the disease. B. pertussis culture has been widely available for many years, and polymerase chain reaction methods have recently been added to the diagnostic repertoire, but in many instances, by the time clinicians suspect pertussis in adults, neither of these studies will have yielded positive results. Although serologic testing will confirm the diagnosis in adults, it is not widely available to clinicians. The CDC and the US Food and Drug Administration have been collaborating to provide a serologic test that would be widely available for clinicians, but it is not yet operational. If the diagnosis of pertussis had been considered sooner for the symptomatic HCW described by Bryant et al.,16 and the diagnosis confirmed by serologic testing, then the entire outbreak in the neonatal ward might have been averted.

Another striking yet all-too-common finding in the outbreak reported by Bryant et al.16 is the difficulty of tracing HCWs exposed to the index patient. Lack of documentation about HCWs who provided key direct patient care activities, such as bathing and feeding, led to an incomplete identification of exposed personnel. Such personnel, if not identified and offered appropriate postexposure prophylaxis, could have caused further disease transmission. Such problems with contact tracing are not unique to B. pertussis exposure, and they serve to emphasize the need to develop more detailed documentation tools to track contact between HCWs and patients.

The report by Bamberger et al.20 demonstrates the global nature of the pertussis problem; it describes 2 outbreaks of nosocomial pertussis at 2 different healthcare facilities in Israel. In both instances, the infected infants resided in adjacent beds, and the probable source of infection was a symptomatic parent of one of the infants. Failure to detect a history of cough in the parent and allowing contact between the parent and other infants in the ward facilitated the nosocomial acquisition of B. pertussis. The restriction of ill visitors in healthcare institutions is often highlighted in strategies to prevent nosocomial spread of respiratory viral infections, such as influenza and respiratory syncytial virus infection. However, questioning and restriction of visitors with a nonfebrile cough illness is often not a component of such policies. As illustrated by the outbreaks in Israel, it must be ensured that coughing visitors (regardless of whether they have a febrile illness) have limited access to patients in the healthcare setting, particularly in high-risk units such as pediatric intensive care units and newborn nurseries. In addition, visitor contact with other patients should be limited. As Bamberger et al.20 suggest, “nurseries should discourage parents from contact with infants other than their own” (p. 624).

Another key issue with regard to nosocomial pertussis is the use of antimicrobial postexposure prophylaxis. For many years, the traditional agent used in postexposure prophylaxis for HCWs exposed to pertussis has been erythromycin. An effective agent in preventing infection in exposed persons,21 the drug’s major drawback is that its use is associated with a substantial occurrence of adverse events, particularly nausea, emesis, and diarrhea. Although newer macrolides with a lower associated frequency of adverse effects have been developed (eg, azithromycin), they were long considered second-line agents for postexposure prophylaxis for pertussis in formal recommendations.23,24 Devasia and colleagues25 evaluated the tolerability of erythromycin and azithromycin postexposure prophylaxis during a community-wide pertussis outbreak in Tennessee. Only 57% of persons who were prescribed erythromycin for postexposure prophylaxis completed the antibiotic course, compared with 94% who were prescribed azithromycin. The medication’s adverse effects (predominantly gastrointestinal) were cited as the reason for nonadherence to therapy by 33% of the erythromycin group, compared with only 4% of the azithromycin group. Before adoption of azithromycin as a first-line option for postexposure prophylaxis, the perceived risk of erythromycin-associated adverse events led to HCWs in our hospital to refuse the provided erythromycin postexposure prophylaxis in favor of azithromycin they paid for out of pocket.

Recently, the CDC released revised recommendations for treatment of and postexposure prophylaxis for pertussis in which any macrolide (erythromycin, azithromycin, or clarithromycin) is considered a first-line agent for postexposure prophylaxis in adults and children.21 For neonates younger than 1 month, azithromycin is the recommended agent for postexposure prophylaxis because of the association of erythromycin with infantile hypertrophic pyloric stenosis. The addition of azithromycin to the first-line agents for postexposure prophylaxis should improve adherence to postexposure prophylaxis, thus reducing secondary transmission of B. pertussis in healthcare facilities.

The outbreak of pertussis in Paris, France, described by Giugliani et al.22 in this issue highlights additional challenges. The authors describe an outbreak of pertussis in an internal medicine ward and their attempt to deliver azithromycin prophylaxis to more than 200 HCWs. Even with the use of azithromycin, 33% of HCWs reported at least 1 adverse event, and 11% of the HCWs refused treatment. As shown in the article by Bryant et al.,16 the refusal of prophylaxis by even a single HCW can set off a second wave of contagion and require additional rounds of prophylaxis. Another interesting finding in the study by Giugliani et al.22 is that, although the adverse effects of erythromycin prophylaxis for pertussis are widely appreciated, the adverse effects associated with the “better tolerated” azithromycin still resulted in discontinuation of therapy by 8% of HCWs. The question of whether HCWs are more willing to tolerate adverse effects of medication for treatment of their own disease than for prevention of disease in others is merely speculative.

Taken together, these 3 informative studies could fill read-
Tdap vaccines in HCWs are needed. However, the recent licensure, in 2005, of 2 acellular pertussis vaccines combined with tetanus and diphtheria toxoids (Tdap vaccines) for use as adolescent boosters (and, for one product, use as an adult booster) is cause for great optimism.\(^1\)\(^2\)\(^6\) Childhood vaccination against \textit{B. pertussis} was first recommended in the 1940s, and at that time pertussis vaccines consisted of diphtheria and tetanus toxoids combined with killed whole-cell \textit{B. pertussis} organisms. These vaccines were associated with high rates of local and systemic adverse effects.\(^9\) A less reactogenic vaccine, which replaced the whole-cell pertussis vaccine with a more highly purified acellular \textit{B. pertussis} component (Tdap), was licensed in 1991. With universal childhood pertussis vaccination, the incidence of pertussis in children has markedly declined.\(^1\) Tdap vaccines are also highly effective in adolescents and adults, as illustrated by the recently published Adult Pertussis Trial.\(^27\) In this randomized, clinical trial, which enrolled more than 2,700 healthy adults and adolescents, administration of an acellular pertussis vaccine was 92% efficacious in preventing pertussis confirmed by culture or serologic testing.\(^27\)

In the past several years, 2 expert groups, the International Consensus Group on Pertussis Immunisation\(^28\) and the Global Pertussis Initiative,\(^29\) have both recommended universal adolescent booster pertussis vaccination combined with targeted vaccination of those adults most likely to have contact with infants, including parents and other close family members, HCWs, and daycare workers; universal vaccination of young adults; and routine use of Tdap vaccines rather than the adult tetanus and diphtheria toxoid vaccine for all adult booster vaccinations. In view of the increasingly recognized problem of healthcare-associated \textit{B. pertussis} infection, the CDC’s Advisory Committee on Immunization Practices targeted HCWs as a priority group for pertussis vaccination in 2006, primarily to reduce the risk of spread of \textit{B. pertussis} within healthcare institutions.\(^26\)

The use of Tdap vaccines for vaccination of HCWs heralds an exciting era in the prevention of nosocomial pertussis; however, questions remain regarding the impact and implementation of Tdap vaccination of HCWs. Does the use of the highly efficacious vaccine eliminate the need for any additional post-exposure prophylaxis for vaccinated HCWs who have been exposed to pertussis? What is the duration of protection in a vaccinated cohort, and should booster vaccinations be given to those at high risk of exposure? If so, how frequently should such booster vaccinations occur? Universal vaccination of HCWs with Tdap vaccines may abolish the need for widespread postexposure prophylaxis and allow limited resources to be directed towards other preventive efforts. It has been estimated that vaccination of HCWs with Tdap vaccines would prevent nearly 50% of \textit{B. pertussis} exposures annually, with an estimated cost savings of $2.38 for each dollar invested in HCW vaccination.\(^15\) Further studies of the cost-effectiveness of the use of Tdap vaccines in HCWs are needed.

Tdap vaccines are additional “patient safety” vaccines that, like influenza vaccine, protect both HCWs and their patients. Given the unacceptably low rates of HCW influenza vaccination (a topic discussed in several articles in this issue of the journal) and the recent push to increase these rates,\(^30\) a similar strategy for enhancing Tdap vaccination of HCWs is also needed. The awareness among HCWs of the importance of nosocomial pertussis, of the overall increase in the burden of \textit{B. pertussis} disease, of the atypical presentation of pertussis in adolescents and adults, and of the rationale for HCW vaccination with Tdap vaccines must be heightened. As with influenza vaccination, Tdap vaccination campaigns must be multifaceted, backed by the healthcare facility’s administration, and adequately supported with financial and human resources. Hopefully, because there is no need for annual revaccination and because there are few concerns about adverse events associated with Tdap vaccines, healthcare facilities can achieve a more acceptable level of adherence to HCW pertussis vaccination than has been historically noted for influenza vaccination.

In summary, the reports in this issue about pertussis in healthcare settings and the difficulties of infection control and postexposure prophylaxis associated with these outbreaks are of great concern. However, the licensure of Tdap vaccines and the demonstration of their efficacy suggest that universal administration of Tdap vaccine to HCWs could markedly reduce, if not possibly eliminate, the challenging problem of healthcare-associated pertussis.

\textbf{REFERENCES}

7. Boulay BR, Murray CJ, Ptak J, Kirkland KB, Montero J, Talbot EA. An outbreak of pertussis in a hematology-oncology care unit: implications...


